Nataliya Mar

1.9k total citations · 1 hit paper
65 papers, 588 citations indexed

About

Nataliya Mar is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nataliya Mar has authored 65 papers receiving a total of 588 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Surgery, 31 papers in Oncology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nataliya Mar's work include Bladder and Urothelial Cancer Treatments (28 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Urinary and Genital Oncology Studies (18 papers). Nataliya Mar is often cited by papers focused on Bladder and Urothelial Cancer Treatments (28 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Urinary and Genital Oncology Studies (18 papers). Nataliya Mar collaborates with scholars based in United States, Spain and France. Nataliya Mar's co-authors include James J. Vredenburgh, Jeffrey S. Wasser, Robert R. Karpman, Arash Rezazadeh Kalebasty, Joshua Cohen, R. W. Graham, Georgia Panagopoulos, Farshid Dayyani, Muhammad Wasif Saif and Jonathan E. Rosenberg and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Nataliya Mar

54 papers receiving 583 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

2023 84 citations Thomas Powles, Begoña P. Valderrama et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nataliya Mar United States	13	298	272	185	104	59	65	588
Tivadar Bara Romania	15	235 0.8×	214 0.8×	180 1.0×	84 0.8×	23 0.4×	68	538
Maximillian Bockhorn Germany	12	179 0.6×	196 0.7×	118 0.6×	116 1.1×	27 0.5×	28	481
Keun Wook Lee South Korea	14	201 0.7×	499 1.8×	299 1.6×	90 0.9×	74 1.3×	41	745
Takeshi Kajiwara Japan	14	292 1.0×	436 1.6×	388 2.1×	94 0.9×	31 0.5×	69	868
Chihiro Kondoh Japan	13	160 0.5×	302 1.1×	241 1.3×	109 1.0×	35 0.6×	49	546
Rebekka Schirren Germany	14	408 1.4×	350 1.3×	228 1.2×	44 0.4×	42 0.7×	29	635
Masahiro Serikawa Japan	12	400 1.3×	424 1.6×	210 1.1×	62 0.6×	59 1.0×	61	620
Mitsuru Sugimoto Japan	16	365 1.2×	298 1.1×	275 1.5×	61 0.6×	42 0.7×	100	722
Mika Takasumi Japan	13	287 1.0×	178 0.7×	224 1.2×	30 0.3×	26 0.4×	83	522
Kozo Miyatani Japan	15	211 0.7×	328 1.2×	282 1.5×	82 0.8×	21 0.4×	80	700

Countries citing papers authored by Nataliya Mar

Since Specialization

Citations

This map shows the geographic impact of Nataliya Mar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nataliya Mar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nataliya Mar more than expected).

Fields of papers citing papers by Nataliya Mar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nataliya Mar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nataliya Mar. The network helps show where Nataliya Mar may publish in the future.

Co-authorship network of co-authors of Nataliya Mar

This figure shows the co-authorship network connecting the top 25 collaborators of Nataliya Mar. A scholar is included among the top collaborators of Nataliya Mar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nataliya Mar. Nataliya Mar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meagher, Margaret, Melissa C. Stoppler, Stamatina Fragkogianni, et al.. (2025). Comprehensive Comparison of Somatic, Germline, and Immune Cell Profiles in Upper Tract and Bladder Urothelial Carcinoma. JCO Precision Oncology. 9(9). e2500289–e2500289.

Friedlander, Terence W., Peter H. O’Donnell, Daniel P. Petrylak, et al.. (2025). 3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y. Annals of Oncology. 36. S1487–S1488.

Harada, Garrett K., Steven N. Seyedin, Armon Azizi, et al.. (2024). A Predictive Nomogram for Development of Lymph Node Metastasis in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy. Advances in Radiation Oncology. 10(1). 101671–101671. 1 indexed citations

Lee, Fa-Chyi, et al.. (2024). A case report of challenges in distinguishing gastroesophageal junction hepatoid adenocarcinoma from testicular germ cell tumor: Insights for improved diagnosis with gene expression profiling. SHILAP Revista de lepidopterología. 12. 2050313X231223469–2050313X231223469. 1 indexed citations

Heijden, Michiel Simon Van Der, Shilpa Gupta, Jens Bedke, et al.. (2024). Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39.. Journal of Clinical Oncology. 42(16_suppl). 4563–4563. 3 indexed citations

Seyedin, Steven N., et al.. (2024). Safety Analysis of Co-Administration of Radiation Therapy with Enfortumab Vedotin Based Regimens in Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer. 22(6). 102243–102243. 1 indexed citations

Sadeghi, Sarmad, Nataliya Mar, Denice Tsao‐Wei, et al.. (2024). Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 42(16_suppl). 4577–4577.

Mar, Nataliya, et al.. (2024). The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond. Cancers. 16(19). 3361–3361.

Levi, Jelena, Millie Das, Deepti Behl, et al.. (2024). [¹⁸F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non–Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy. Journal of Nuclear Medicine. 65(12). jnumed.124.268253–jnumed.124.268253. 1 indexed citations

10.

Mar, Nataliya, et al.. (2024). Diversity among editorial boards of genitourinary oncology journals.. Journal of Clinical Oncology. 42(4_suppl). 481–481.

11.

Powles, Thomas, Begoña P. Valderrama, Shilpa Gupta, et al.. (2023). 211MO EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Annals of Oncology. 34. S1557–S1558. 1 indexed citations

12.

Mar, Nataliya, Kevin Zarrabi, Shuchi Gulati, et al.. (2023). Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC). Clinical Genitourinary Cancer. 22(2). 217–223.

13.

Powles, Thomas, Begoña P. Valderrama, Shilpa Gupta, et al.. (2023). LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Annals of Oncology. 34. S1340–S1340. 84 indexed citations breakdown →

14.

Mar, Nataliya, Yousef Zakharia, Alejandro Falcón, et al.. (2023). Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma. Cancers. 15(11). 2978–2978. 1 indexed citations

15.

Benjamin, David J., Nataliya Mar, & Arash Rezazadeh Kalebasty. (2022). Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma. Clinical Medicine Insights Oncology. 16. 1363247212–1363247212. 10 indexed citations

16.

Mar, Nataliya, et al.. (2022). Late recurrence of localized pure seminoma in prostate gland: A case report. World Journal of Clinical Oncology. 13(1). 62–70. 1 indexed citations

17.

Mar, Nataliya, Edward Uchio, & Arash Rezazadeh Kalebasty. (2022). Use of immunotherapy in clinical management of genitourinary cancers – a review. Cancer Treatment and Research Communications. 31. 100564–100564. 3 indexed citations

18.

Yu, Evan Y., Josep M. Piulats, Gwénaëlle Gravis, et al.. (2020). 621P Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update. Annals of Oncology. 31. S513–S514. 5 indexed citations

19.

Mar, Nataliya & James J. Vredenburgh. (2015). Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation.. PubMed. 79(9). 531–5. 2 indexed citations

20.

Mar, Nataliya, et al.. (2014). Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss. Journal of Thrombosis and Thrombolysis. 38(2). 196–200. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact